Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial by Uhrenholt, L, Duch, K, Christensen, R, Dreyer, L, Hauge, E-M, Schlemmer, A, Taylor, PC, Kristensen, S

Agreement between patient-reported outcome measures collected via a smartphone application vs a touchscreen solution in an outpatient clinic among patients with inflammatory arthri... by Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E-M, Krogh, NS, Abildtoft, MK, Taylor, PC, Kristensen, S

Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: A randomised, crossover, agreement study by Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E-M, Krogh, NS, Abildtoft, M, Taylor, PC, Kristensen, S

Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a... by Uhrenholt, L, Christensen, R, Dinesen, WKH, Liboriussen, CH, Andersen, SS, Dreyer, L, Schlemmer, A, Hauge, E-M, Skrubbeltrang, C, Taylor, PC, Kristensen, S

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial by Uhrenholt, L, Sørensen, MER, Lauridsen, KB, Duch, K, Dreyer, L, Christensen, R, Hauge, E-M, Loft, AG, Rasch, MNB, Horn, HC, Taylor, PC, Nielsen, KR, Kristensen, S

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial by Uhrenholt, L, Christensen, R, Dreyer, L, Hauge, E-M, Schlemmer, A, Loft, AG, Rasch, M, Horn, HC, Gade, KH, Østgård, RD, Taylor, PC, Duch, K, Kristensen, S